Claims for Patent: 9,943,537

Summary for Patent: 9,943,537

Title:	Antitumor agent and antitumor effect enhancer
Abstract:	Provided is a novel method for treating a cancer using an FTD/TPI combination drug, which shows remarkably excellent antitumor effect and small adverse effects. An antitumor agent, in which a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 and an anti-VEGF antibody or anti-EGFR antibody are administered in combination.
Inventor(s):	Okabe; Hiroyuki (Hanno, JP)
Assignee:	TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP)
Application Number:	14/916,878
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,943,537
Patent Claims:	1. A method for treating a cancer, comprising: administering to a subject in need thereof 17 to 115% of a recommended daily dose of a combination drug comprising trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5, and 11 to 100% of a recommended daily dose of an antibody selected from the group consisting of bevacizumab, cetuximab, and panitumumab, in combination. 2. The method of claim 1, wherein the antibody is bevacizumab. 3. The method of claim 1, wherein the antibody is cetuximab. 4. The method of claim 1, wherein the cancer is at least one selected from the group consisting of colorectal cancer, lung cancer, breast cancer, pancreatic cancer, and gastric cancer. 5. The method of claim 1, wherein the antibody is panitumumab. 6. A method for treating a cancer, comprising: administering to a subject in need thereof 11 to 80 mg/m.sup.2/day of a combination drug comprising trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5, and 1.10 to 10 mg/kg/day of bevacizumab, in combination. 7. A method for treating a cancer, comprising: administering to a subject in need thereof 11 to 80 mg/m.sup.2/day of a combination drug comprising trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5, and 44 to 400 mg/m.sup.2/day of cetuximab, in combination. 8. A method for treating a cancer, comprising: administering to a subject in need thereof 11 to 80 mg/m.sup.2/day of a combination drug comprising trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5, and 0.68 to 6 mg/kg/day of panitumumab, in combination. 9. The method of claim 6, wherein a daily dose of the combination drug is from 17 to 115% of a recommended daily dose of the combination drug alone, and a daily dose of bevacizumab is from 11 to 100% of a recommended daily dose of bevacizumab alone. 10. The method of claim 7, wherein a daily dose of the combination drug is from 17 to 115% of a recommended daily dose of the combination drug alone, and a daily dose of cetuximab is from 11 to 100% of a recommended daily dose of cetuximab alone. 11. The method of claim 8, wherein a daily dose of the combination drug is from 17 to 115% of a recommended daily dose of the combination drug alone, and a daily dose of panitumumab is from 11 to 100% of a recommended daily dose of panitumumab alone. 12. The method of claim 6, wherein 35 to 70 mg/m.sup.2/day of the combination drug is administered to the subject. 13. The method of claim 6, wherein the combination drug is administered such that 70 mg/m.sup.2/day of trifluridine is administered to the subject. 14. The method of claim 7, wherein 35 to 70 mg/m.sup.2/day of the combination drug is administered to the subject. 15. The method of claim 7, wherein the combination drug is administered such that 70 mg/m.sup.2/day of trifluridine is administered to the subject. 16. The method of claim 8, wherein 35 to 70 mg/m.sup.2/day of the combination drug is administered to the subject. 17. The method of claim 8, wherein the combination drug is administered such that 70 mg/m.sup.2/day of trifluridine is administered to the subject. 18. The method of claim 6, wherein the cancer is at least one selected from the group consisting of colorectal cancer, lung cancer, breast cancer, pancreatic cancer, and gastric cancer. 19. The method of claim 7, wherein the cancer is at least one selected from the group consisting of colorectal cancer, lung cancer, breast cancer, pancreatic cancer, and gastric cancer. 20. The method of claim 8, wherein the cancer is at least one selected from the group consisting of colorectal cancer, lung cancer, breast cancer, pancreatic cancer, and gastric cancer.

Details for Patent 9,943,537

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2033-09-06
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2033-09-06
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-09-06
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2033-09-06